Profile data is unavailable for this security.
About the company
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.
- Revenue in GBP (TTM)36.76bn
- Net income in GBP4.78bn
- Incorporated1992
- Employees89.90k
- LocationAstraZeneca PLC1 Francis Crick AvenueCAMBRIDGE CB2 0AAUnited KingdomGBR
- Phone+44 207 304 5000
- Fax+44 207 604 8151
- Websitehttps://www.astrazeneca.com/
Mergers & acquisitions
| Acquired company | AZN:LSE since announced | Transaction value |
|---|---|---|
| Fusion Pharmaceuticals Inc | 16.87% | 2.30bn |
| Amolyt Pharma SAS | 14.99% | 1.05bn |
| Gracell Biotechnologies Inc | 15.24% | 1.10bn |
| Icosavax Inc | 19.12% | 862.87m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck KGaA | 18.02bn | 2.43bn | 56.86bn | 62.91k | 23.45 | 2.48 | 14.35 | 3.16 | 6.50 | 6.50 | 48.27 | 61.36 | 0.4327 | 1.86 | 5.03 | 333,709.50 | 5.84 | 5.64 | 7.20 | 7.27 | 59.03 | 61.86 | 13.49 | 12.97 | 0.8916 | 32.81 | 0.2694 | 9.26 | -5.57 | 7.19 | -15.09 | 21.40 | 14.77 | 11.97 |
| GSK plc | 30.33bn | 4.93bn | 67.81bn | 70.21k | 13.60 | 4.97 | 8.31 | 2.24 | 1.20 | 1.20 | 7.39 | 3.29 | 0.5091 | 1.57 | 4.20 | 431,949.00 | 8.91 | 6.74 | 13.91 | 10.71 | 72.42 | 70.29 | 17.50 | 16.93 | 0.624 | 10.99 | 0.5848 | 79.55 | 3.42 | -0.322 | 15.79 | 7.10 | 5.47 | -10.32 |
| Sanofi SA | 39.87bn | 4.64bn | 95.23bn | 87.99k | 20.40 | 1.48 | 14.36 | 2.39 | 4.30 | 4.30 | 37.04 | 59.17 | 0.3669 | 1.53 | 5.51 | 527,808.70 | 4.38 | 5.87 | 5.43 | 7.16 | 69.35 | 68.78 | 11.95 | 16.90 | 0.8675 | 66.19 | 0.1986 | 60.51 | 2.32 | 5.42 | -35.49 | 4.57 | 8.87 | 4.14 |
| Roche Holding AG | 51.48bn | 10.08bn | 159.25bn | 103.61k | 15.54 | 6.04 | 11.48 | 3.09 | 14.30 | 14.30 | 73.03 | 36.77 | 0.6574 | 1.91 | 5.19 | 566,729.40 | 13.84 | 16.12 | 20.84 | 25.24 | 73.39 | 71.48 | 21.05 | 22.98 | 1.04 | 20.77 | 0.4676 | 58.80 | -7.21 | 0.6494 | -7.43 | 1.90 | 10.01 | 1.99 |
| Novartis AG | 38.29bn | 7.31bn | 171.72bn | 76.06k | 22.16 | 4.82 | 12.30 | 4.48 | 4.04 | 6.74 | 21.07 | 18.55 | 0.4621 | 1.78 | 5.70 | 574,186.80 | 8.82 | 8.53 | 12.43 | 11.23 | 74.61 | 72.93 | 19.09 | 22.68 | 0.7069 | 13.99 | 0.4062 | 67.20 | 7.57 | 0.2779 | 41.64 | -7.71 | 0.7808 | 6.19 |
| AstraZeneca plc | 36.76bn | 4.78bn | 175.80bn | 89.90k | 37.05 | 5.60 | 19.30 | 4.78 | 3.06 | 3.06 | 23.54 | 20.26 | 0.4637 | 1.59 | 4.05 | 408,935.80 | 6.03 | 3.34 | 8.47 | 4.61 | 82.39 | 79.64 | 13.01 | 7.69 | 0.6427 | 6.34 | 0.4222 | 143.06 | 3.29 | 15.71 | 81.11 | 22.54 | 22.47 | 1.10 |
| Novo Nordisk A/S | 26.73bn | 9.63bn | 347.40bn | 63.37k | 47.19 | 36.76 | 33.18 | 13.00 | 18.62 | 18.62 | 51.68 | 23.90 | 0.8359 | 1.27 | 4.03 | 3,665,157.00 | 30.12 | 29.17 | 63.12 | 58.62 | 84.60 | 83.93 | 36.03 | 33.55 | 0.6356 | -- | 0.2022 | 50.13 | 31.26 | 15.74 | 50.71 | 16.72 | 25.67 | 18.20 |
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Investment Management (UK) Ltd.as of 31 Dec 2023 | 68.51m | 4.42% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 65.12m | 4.20% |
| The Vanguard Group, Inc.as of 01 Apr 2024 | 56.87m | 3.67% |
| Norges Bank Investment Managementas of 01 Apr 2024 | 34.36m | 2.22% |
| BlackRock Fund Advisorsas of 01 Apr 2024 | 29.74m | 1.92% |
| BlackRock Advisors (UK) Ltd.as of 01 Apr 2024 | 22.21m | 1.43% |
| SSgA Funds Management, Inc.as of 01 Apr 2024 | 15.52m | 1.00% |
| Legal & General Investment Management Ltd.as of 01 Apr 2024 | 15.37m | 0.99% |
| BlackRock Advisors LLCas of 01 Apr 2024 | 15.35m | 0.99% |
| Schroder Investment Management Ltd.as of 01 Apr 2024 | 12.66m | 0.82% |
